Algorae Pharmaceuticals Ltd Wins NSW Health Public Hospital Supply Contract [VIDEO]
Algorae Pharmaceuticals (ASX: 1AI) has won a competitive NSW Health public hospital supply contract through its AlgoraeRx division, securing up to five years of access to one of Australia's largest healthcare procurement networks with first supply expected in Q4 2026.
Key Takeaways
- Algorae Pharmaceuticals has been awarded a NSW Health public hospital supply contract through its AlgoraeRx division following a competitive tender, securing access to one of Australia's largest public healthcare procurement networks.
- The contract runs for an initial three years with two optional one-year extensions (3+1+1 structure), and onboarding is already underway with first supply targeted for Q4 2026.
- Financial terms including pricing and volumes are confidential, meaning Algorae cannot quantify the revenue impact — investors are pricing market access rather than a disclosed contract value.
- The NSW Health win anchors the near-term commercial arm of Algorae's dual-track strategy, which pairs AlgoraeRx's pharmaceutical distribution business with the AlgoraeOS AI drug discovery platform validated by Peter MacCallum Cancer Centre.
- Algorae's existing Zydus Lifesciences partnership, covering exclusive distribution of injectable, oral and specialty products across hospital and community care channels in Australia and New Zealand, provides the product base to fulfil the NSW Health contract.
![Genetic Signatures Ltd Gets BCAL Backing Through 10.2% Stake Purchase [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fb377bf6c-56e4-43e5-9dd1-8e08cd86e8c82Fimage_0.jpg)
![Algorae Pharmaceuticals Ltd Clarifies NSW Health Supply Panel Terms [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fbad3a004-c24a-4185-95c9-6312cede3da92Fimage_0.jpg)
![Imugene Ltd Reports Second Complete Response in BTKi Cohort [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2F352176a6-56e8-4d9b-a769-8060d34f35502Fimage_0.jpg)
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.